Insulin Glulisine

Summary

Insulin Glulisine (CHEMBL1201613) is an approved protein (ATC A10AB06); indicated across 6 conditions including diabetes mellitus and type 1 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: A10AB06
• Indications: 6 conditions
• Clinical trials: 73

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201613
Name	Insulin Glulisine
Type	Protein
Max phase	4
ATC	A10AB06

Also known as: Apidra, Glulisine apidra, HMR 1964, HMR-1964, HMR1964, Ins apidra, Ins apidra opticlik, Ins apidra optiset, Ins apidra solostar, Insulin glulisine, Insulin glulisine recombinant, Insulin

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 1 diabetes mellitus	3	MONDO:0005147	MONDO:0005147
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
acute myocardial infarction	3	MONDO:0004781	EFO:0008583
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
Down syndrome	1	MONDO:0008608	EFO:0001064

Clinical trials

Total trials: 73.

Phase distribution

Phase	Trials
PHASE4	35
PHASE3	19
PHASE1	11
PHASE2	5
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00283049	PHASE4	TERMINATED	Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
NCT00360698	PHASE4	COMPLETED	Insulin Glulisine in Type 2 Diabetic Patients
NCT00384085	PHASE4	COMPLETED	Insulin Glargine All to Target Trial
NCT00489190	PHASE4	COMPLETED	APIDRA Registration Study
NCT00526513	PHASE4	COMPLETED	Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
NCT00539448	PHASE4	COMPLETED	Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
NCT00596687	PHASE4	COMPLETED	Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
NCT00607087	PHASE4	COMPLETED	Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
NCT00913497	PHASE4	COMPLETED	The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
NCT00964574	PHASE4	COMPLETED	Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
NCT00965549	PHASE4	COMPLETED	Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
NCT01079364	PHASE4	TERMINATED	Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
NCT01081938	PHASE4	TERMINATED	Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
NCT01121835	PHASE4	COMPLETED	Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
NCT01122979	PHASE4	COMPLETED	Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
NCT01131052	PHASE4	COMPLETED	Diabetes in the Elderly: Prospective Study
NCT01202474	PHASE4	COMPLETED	Apidra Children & Adolescents Study
NCT01203111	PHASE4	COMPLETED	Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
NCT01204593	PHASE4	COMPLETED	baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
NCT01212913	PHASE4	COMPLETED	Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
NCT01234597	PHASE4	COMPLETED	Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
NCT01417897	PHASE4	UNKNOWN	Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study
NCT01500850	PHASE4	UNKNOWN	Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
NCT01594060	PHASE4	COMPLETED	Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
NCT01678235	PHASE4	COMPLETED	Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
NCT01848990	PHASE4	COMPLETED	CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
NCT02048189	PHASE4	TERMINATED	Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes
NCT02276196	PHASE4	COMPLETED	Effect of LIXIsenatide on the Renal System
NCT02276859	PHASE4	COMPLETED	Normal Versus Dual Wave Insulin Bolus for High-protein Food
NCT02685449	PHASE4	UNKNOWN	Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
NCT02914886	PHASE4	COMPLETED	Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
NCT03328845	PHASE4	COMPLETED	Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)
NCT03359837	PHASE4	COMPLETED	Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
NCT04019821	PHASE4	COMPLETED	Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
NCT04124302	PHASE4	COMPLETED	The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
NCT00046150	PHASE3	COMPLETED	12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
NCT00115570	PHASE3	COMPLETED	Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
NCT00135057	PHASE3	COMPLETED	Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
NCT00135083	PHASE3	COMPLETED	Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
NCT00135096	PHASE3	COMPLETED	Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).